Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Core Insights - Cullinan Therapeutics, Inc. is actively participating in investor conferences and hosting an event at the 2025 ASH Annual Meeting to showcase its advancements in therapies for autoimmune diseases and cancer [1][4] Company Overview - Cullinan Therapeutics, Inc. (Nasdaq: CGEM) focuses on developing first- or best-in-class therapies for autoimmune diseases and cancer, leveraging expertise in T cell engagers [3] - The company is committed to delivering new standards of care through a clinical-stage pipeline built on rigorous scientific approaches and purposeful innovation [3] Upcoming Events - The management team, including CEO Nadim Ahmed and CMO Jeffrey Jones, will participate in fireside chats at the Stifel 2025 Healthcare Conference on November 11, 2025, and the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025 [4] - An in-person event for analysts and institutional investors is scheduled for December 8, 2025, during the ASH Annual Meeting, following the presentation of Phase 1 study results for CLN-049 in patients with AML or MDS [4]